Compare Recursion Pharmaceuticals Inc (RXRX) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? Recursion Pharmaceuticals Inc trades at $3.07 (market cap $1.53B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.9. The key difference: State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | SJNK | |
|---|---|---|
Market Cap | $1.53B | — |
Sector | Health | Sector/Thematic |
52-Week High | $6.79 | $25.63 |
52-Week Low | $2.84 | $24.75 |
Enterprise Value | $946.50M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $2.89, down 1.87% on the day, reflecting a challenging fundamental backdrop with a net income margin of -851.51% and negative cash flow from operations. The technical picture is bearish, though the stock has beaten earnings estimates for the last three quarters. Recent news highlights its AI-driven drug discovery platform and significant institutional interest, including purchases by Cathie Wood's Ark Invest.
The outlook remains speculative; the high analyst price target of $7.83 suggests significant upside potential, but this is contingent on the company successfully commercializing its pipeline. Key risks include persistent cash burn, intense competition, and the inherent uncertainty of clinical-stage biotech development.
SJNK trades at $24.92 with no price change in the last 24 hours, showing technical bearish signals from moving averages while oscillators remain neutral. The ETF maintains consistent dividend payments with recent distributions of $0.14-$0.15 per share. Current technical analysis indicates bearish momentum with key support and resistance clustered around $25 levels.
The short-term high-yield bond ETF faces headwinds from potential yield normalization after benefiting from falling rates. Analyst sentiment appears cautious with recent bearish ratings citing exhausted tailwinds. Key risks include interest rate sensitivity and credit spread volatility in the junk bond market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
